TrialReader


Long-Term Multi-center Evaluation of E-Poly and Regenerex

NCT00545285 — Not applicable, Unknown, 1000 participants, Massachusetts General Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Long-Term Multi-center Evaluation of E-Poly and Regenerex Cementless Acetabular Components: Clinical and Radiographic Outcomes

RegistryNCT00545285
StatusUnknown
PhaseNot applicable
Study typeInterventional; non randomized, parallel, masking: none, treatment
Enrollment1000 (Estimated)
SponsorMassachusetts General Hospital (Other); collaborators: Zimmer Biomet
ConditionsOsteoarthritis of Hip, Traumatic Arthritis of Hip
InterventionsTotal Hip Arthroplasty (Procedure)
Datesstart 2007-11-01, primary completion 2023-05-01 (estimated), completion 2023-05-01 (estimated), first posted 2007-10-17, last updated 2017-05-03
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Osteoarthritis of Hip All trials for Traumatic Arthritis of Hip All trials of Total Hip Arthroplasty

-Summary

There are two distinct aims of this study:

1. This prospective study is designed to document the long-term (10-year) radiographic and clinical outcomes of a new type of highly cross-linked polyethylene liner which contains vitamin E as an anti-oxidant, (E-Poly), in a group of primary total hip arthroplasty subjects. The clinical outcome of E-Poly will be compared to a group of subjects receiving Arcom XL polyethylene.
2. This study is also designed to document the long-term (10-year) radiographic and clinical outcomes of a new cementless acetabular component having a titanium porous surface (Regenerex). The clinical outcome of this new FDA cleared device will be compared a group of subjects receiving an acetabular component having a plasma sprayed surface.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
1Active comparatorProcedure: Total Hip ArthroplastyTotal hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
2Active comparatorProcedure: Total Hip ArthroplastyTotal hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
3Active comparatorProcedure: Total Hip ArthroplastyTotal hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
4Active comparatorProcedure: Total Hip ArthroplastyTotal hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
  • Total Hip Arthroplasty (Procedure): Surgical implantation of specific hip replacement components for treatment of osteoarthritis

+Outcome measures

Primary outcomes

  • Survivorship: length of time implant remains without revision [Evaluated at 1,3,5,7 ,10th year over 10 years]
  • Complications and Adverse Events [Evaluated at 1,3,5,7 ,10th year over 10 years]
  • Incidence of radiolucencies (acetabular component) [Evaluated at 1,3,5,7 ,10th year over 10 years]
  • Patient administered Outcome Survey scores [Evaluated at 1,3,5,7 ,10th year over 10 years]
  • Polyethylene wear rates from AP radiographs [Evaluated at 1,3,5,7 ,10th year over 10 years]

Secondary outcomes

  • Survivorship in subcategories of infection, aseptic loosening and other [1,3,5,7,10 yr over 10 years]
  • Subcategories of the outcome scores regarding pain, patient satisfaction, function,general quality of life. [1,3,5,7,10 yr over 10 years]
  • Other outcomes that may be relevant. [1,3,5,7,10 yr over 10 years]
  • Retrieval analysis [1,3,5,7,10 yr over 10 years]

+Eligibility

Sex: All, ages: 20 Years to 75 Years

Inclusion Criteria:

* Subjects requiring primary total hip replacement
* Subjects with diagnosis of osteoarthritis or traumatic arthritis
* Subjects who demonstrate the ability to return for follow-up for the next 10 years

Exclusion Criteria:

* Subjects with limited life span
* Subjects with difficulty in comprehending study protocol for any reason.
* Subjects with inflammatory disease, previous infection or those requiring revision hip surgery.
* Subjects with avascular necrosis
* Subjects whose bony structures are so small that a femoral head less than 32mm in diameter must be used.
* Subjects whose bony structure deviates substantially from the general norm sufficiently to require non-standard techniques and non-standard implants. Specific examples of these are total dislocation of the hip, severe coxa vera deformity, severe forms of multiple epiphyseal dysplasia
* Subjects with complex disease entities which significantly increase the risks of the surgery such as any major platelet abnormality, hematological disorder, positive for HIV or any other major medical complication which substantially reduces longevity.
* Female subjects that are pregnant or who may suspect they are pregnant or who plan to become pregnant while participating in this study.

+Locations (1)

FacilityCityCountryStatus
Massachusetts General HospitalBoston, MassachusettsUnited States

+Publications

  • Results publication: Sillesen NH, Greene ME, Nebergall AK, Huddleston JI, Emerson R, Gebuhr P, Troelsen A, Malchau H. 3-year follow-up of a long-term registry-based multicentre study on vitamin E diffused polyethylene in total hip replacement. Hip Int. 2016 Jan-Feb;26(1):97-103. doi: 10.5301/hipint.5000297. Epub 2015 Dec 11. PMID 26692248

+Investigators

My Notes